Drugs / Autologous genetically modified gamma-delta T cells
Autologous genetically modified gamma-delta T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05664243 | Sep 2023 → Dec 2025 overdue | glioblastoma | In8bio Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-07-09 | In8bio Inc. | Results IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma in8bio.com ↗
Repeat-dose patients achieved median progression-free survival (mPFS) of 16.1 months, more than double the ~6.9-month standard of care benchmark, with no dose-limiting toxicities (DLTs) |
| 2026-06-01 | In8bio Inc. | Results IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026 in8bio.com ↗
Among patients who received up to six repeat doses of genetically modified gamma delta (γδ) T cells (DeltEx DRI), median progression-free survival (mPFS) reached 13.0 months, nearly double the 6.6 months observed in patients receiving standard-of-care (SOC) alone. |
| 2026-05-14 | In8bio Inc. | Results IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma in8bio.com ↗
Multidimensional analyses demonstrate that repeated DeltEx DRI dosing preserves immune function, drives tumor microenvironment remodeling, and correlates with improved survival outcomes in glioblastoma |
| 2026-01-12 | In8bio Inc. | Results IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma in8bio.com ↗
Patients in both the Phase 1 and 2 who received repeated doses of the Company’s investigational therapy, DeltEx™ Drug-Resistant Immunotherapy gamma-delta (γδ) T cells (DeltEx DRI) (N=14), experienced substantial improvements in both median progression-free (mPFS) and median overall survival (mOS) across multiple clinical centers. |
All press releases naming this drug 4 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous genetically modified gamma-delta T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05664243 ↗ |
| Known as | DeltEx | “This is a Phase 1b and 2 open-label cellular therapy trial using genetically modified gamma-delta (γδ) T cells or DeltEx Drug Resistant Immunotherapy (DRI).” NCT05664243 ↗ |
| Known as | DRI | “This is a Phase 1b and 2 open-label cellular therapy trial using genetically modified gamma-delta (γδ) T cells or DeltEx Drug Resistant Immunotherapy (DRI).” NCT05664243 ↗ |
| Route | Other | “are administered through a catheter directly into the brain” NCT05664243 ↗ |